BR112012029628A2 - formulações lipossômicas melhoradas de compostos lipofílicos - Google Patents

formulações lipossômicas melhoradas de compostos lipofílicos

Info

Publication number
BR112012029628A2
BR112012029628A2 BR112012029628A BR112012029628A BR112012029628A2 BR 112012029628 A2 BR112012029628 A2 BR 112012029628A2 BR 112012029628 A BR112012029628 A BR 112012029628A BR 112012029628 A BR112012029628 A BR 112012029628A BR 112012029628 A2 BR112012029628 A2 BR 112012029628A2
Authority
BR
Brazil
Prior art keywords
liposome
liposomal formulations
lipophilic compounds
preparation
dispersions
Prior art date
Application number
BR112012029628A
Other languages
English (en)
Other versions
BR112012029628B8 (pt
BR112012029628B1 (pt
Inventor
Haas Heinrich
Fattler Ursula
Original Assignee
Medigene Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag filed Critical Medigene Ag
Publication of BR112012029628A2 publication Critical patent/BR112012029628A2/pt
Publication of BR112012029628B1 publication Critical patent/BR112012029628B1/pt
Publication of BR112012029628B8 publication Critical patent/BR112012029628B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

formulações lipossômicas melhoradas de compostos lipofílicos. a presente invenção refere-se à preparação de lipossimas com capacidade de carga realçada para agentes farmaceuticamente e/ou diagnosticamente ativos e/ou agentes comésticos que são substancialmente solubilizados pelas membranas lipossômicas, às dispersões de lipossoma com estabilidade realçada com respeito à liberação do agente ativo e/ou agente cosmético dos lipossomas obtenível pelo processo, e às composições farmacêuticas ou cosméticas compreendendo as referidas dispersões de lipossoma estabilizadas. a preparação pode envolver as etapas de desidratação e reidratação de dispersões de lipossoma que podem ser realizadas por secagem por spray.
BR112012029628A 2010-05-21 2011-05-20 Preparação lipossômica contendo placlitaxel com gradiente de osmolaridade distinto entre as fases aquosas dentro e fora dos lipossomas, seus processos de fabricação, e suspensão lipossômica BR112012029628B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34722210P 2010-05-21 2010-05-21
US61/347,222 2010-05-21
EP10163643A EP2394640A1 (en) 2010-05-21 2010-05-21 Improved liposomal formulations of lipophilic compounds
EP10163643.9 2010-05-21
PCT/EP2011/058275 WO2011144745A2 (en) 2010-05-21 2011-05-20 Improved liposomal formulations of lipophilic compounds

Publications (3)

Publication Number Publication Date
BR112012029628A2 true BR112012029628A2 (pt) 2017-07-04
BR112012029628B1 BR112012029628B1 (pt) 2022-08-30
BR112012029628B8 BR112012029628B8 (pt) 2022-09-20

Family

ID=42752328

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029628A BR112012029628B8 (pt) 2010-05-21 2011-05-20 Preparação lipossômica contendo placlitaxel com gradiente de osmolaridade distinto entre as fases aquosas dentro e fora dos lipossomas, seus processos de fabricação, e suspensão lipossômica

Country Status (18)

Country Link
US (1) US10413511B2 (pt)
EP (2) EP2394640A1 (pt)
JP (1) JP5966168B2 (pt)
KR (2) KR101984454B1 (pt)
CN (1) CN103002876B (pt)
AU (1) AU2011254553B2 (pt)
BR (1) BR112012029628B8 (pt)
CA (1) CA2796806C (pt)
ES (1) ES2640563T3 (pt)
HU (1) HUE036459T2 (pt)
IL (1) IL222406A0 (pt)
MX (1) MX353677B (pt)
MY (1) MY162921A (pt)
PL (1) PL2571492T3 (pt)
RU (1) RU2641605C2 (pt)
SG (1) SG184794A1 (pt)
WO (1) WO2011144745A2 (pt)
ZA (1) ZA201206557B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103181897B (zh) * 2011-12-30 2015-06-10 沈阳药科大学 吉非替尼脂质体制剂及其制备方法
AU2013292636A1 (en) * 2012-07-18 2015-02-05 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
ES2836772T3 (es) 2014-04-30 2021-06-28 Fujifilm Corp Composición liposomal y método para producirla
WO2015166987A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
JP6263609B2 (ja) * 2014-04-30 2018-01-17 富士フイルム株式会社 リポソーム組成物及びその製造方法
ES2826896T3 (es) 2015-05-04 2021-05-19 Versantis AG Método para preparar vesículas con gradiente de pH transmembrana
JP2018516964A (ja) * 2015-06-09 2018-06-28 サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
US10456360B2 (en) 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
KR102084340B1 (ko) * 2015-11-02 2020-03-03 후지필름 가부시키가이샤 젬시타빈 리포솜 조성물을 포함하는 종양 치료제 및 키트
EP3377043A4 (en) * 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
US11344628B2 (en) 2016-08-12 2022-05-31 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
WO2018031979A1 (en) * 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
JP7079250B2 (ja) * 2016-08-18 2022-06-01 ブレマー，トロイ リポソーム構築物を用いた黄斑細胞及び網膜細胞への尿素の送達
BE1024189B1 (nl) * 2016-10-28 2017-12-05 Yun NV Spuitbus met bacteriële species
US11260028B2 (en) * 2017-06-26 2022-03-01 Fordoz Pharma Corp. Nanosome formulations of aprepitant and methods and applications thereof
KR102072439B1 (ko) * 2018-01-29 2020-02-03 한국과학기술연구원 친환경 용매를 이용한 리포좀 제조방법
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC PRALATREXATE ALPHA-POLYGLUTAMATE AND ASSOCIATED USES
JP7491572B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化ペメトレキセドおよびその使用
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC PRALATREXATE GAMMA-POLYGLUTAMATE AND ASSOCIATED USES
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
TWI848045B (zh) * 2019-01-30 2024-07-11 德商巴地斯顏料化工廠 供個人護理應用之液晶脂質顆粒之化妝品組合物
JP2019218392A (ja) * 2019-08-30 2019-12-26 ズリ・ホールディングス・リミテッドＺｕｌｉ Ｈｏｌｄｉｎｇｓ Ｌｔｄ リポソーム、およびリポソームを含む処方剤
CN112891308A (zh) * 2019-12-04 2021-06-04 杏国新药股份有限公司 脂质体制剂
JPWO2021221167A1 (pt) * 2020-04-30 2021-11-04
WO2024160828A1 (en) 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
CN117568255B (zh) * 2024-01-17 2024-04-30 南京邮电大学 一种细胞膜表面张力调控方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (pt) 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (fr) 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
AU587472B2 (en) 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US5089181A (en) 1987-02-24 1992-02-18 Vestar, Inc. Method of dehydrating vesicle preparations for long term storage
CA1335348C (en) 1988-03-04 1995-04-25 Yasuaki Ogawa Liposome composition
JP2931981B2 (ja) 1988-03-04 1999-08-09 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
DK0706373T3 (da) * 1992-03-23 2000-09-18 Univ Georgetown Liposomindkapslet taxol og en fremgangsmåde til anvendelse heraf
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
JP3026271U (ja) 1995-12-25 1996-07-02 株式会社ノガミボーリングサービス 残ピン自動検出機能付きボウリングゲーム装置
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
CN1156269C (zh) * 1999-07-16 2004-07-07 阿尔萨公司 抗冻/融损害的脂质体组合物
ES2272496T3 (es) * 2000-02-04 2007-05-01 Lipoxen Technologies Limited Procedimiento de deshidratacion/rehidritacion para la preparacion de lipososmas.
EP2108362B1 (en) * 2002-06-26 2013-05-29 MediGene AG A cationic liposomal preparation comprising a taxane
EP1393719A1 (en) * 2002-08-23 2004-03-03 Munich Biotech AG Camptothecin-carboxylate formulations
DE60326348D1 (de) 2002-07-15 2009-04-09 Biotechnolog Forschung Gmbh Makrozyclen zur behandlung von krebserkrankungen
DE60328516D1 (de) 2002-11-28 2009-09-03 Wolfgang Richter Thia-epothilon derivate zur krebsbehandlung
WO2004069224A2 (en) 2003-02-03 2004-08-19 Neopharm, Inc. Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
CN100427064C (zh) * 2003-04-16 2008-10-22 沈阳药科大学 一种制备脂质体的新方法
CA2530224A1 (en) * 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
DE10344882A1 (de) 2003-09-26 2005-04-21 Morphochem Ag Komb Chemie Neue Makrocyclen zur Behandlung von Krebserkrankungen
EP2286794B8 (en) 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Use of cationic liposomes comprising paclitaxel
DE10355223A1 (de) 2003-11-26 2005-06-30 Institut für Pflanzenbiochemie (IPB) Neue Makrocyclen zur Behandlung von Krebserkrankungen
EP1750673B1 (en) * 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2006031857A2 (en) * 2004-09-13 2006-03-23 Gilead Sciences, Inc. Delivering iron to an animal
WO2006050327A2 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
WO2006055903A1 (en) * 2004-11-18 2006-05-26 Celator Pharmaceuticals, Inc. Method for loading multiple agents into delivery vehicles
EP1896007B1 (en) 2005-05-04 2014-03-19 Medigene AG Method of administering a cationic liposomal preparation comprising paclitexel
US20070014845A1 (en) 2005-07-01 2007-01-18 Yuanpeng Zhang Liposomal delivery vehicle for hydrophobic drugs
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
EP1795184A1 (en) * 2005-12-09 2007-06-13 Ludwig-Maximilians-Universität München Preparation of powders containing colloidal particles
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
EP1920765A1 (en) * 2006-11-07 2008-05-14 Medigene AG Liposome preparation by single-pass process
CN101444514B (zh) 2008-12-29 2011-07-06 海南灵康制药有限公司 一种注射用头孢甲肟脂质体制剂及其制备方法
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
US20130052259A1 (en) * 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation

Also Published As

Publication number Publication date
JP2013526563A (ja) 2013-06-24
EP2571492A2 (en) 2013-03-27
MX2012013528A (es) 2013-04-03
AU2011254553B2 (en) 2015-02-05
KR20130085368A (ko) 2013-07-29
CN103002876B (zh) 2015-12-02
EP2571492B1 (en) 2017-07-26
CA2796806C (en) 2019-07-16
PL2571492T3 (pl) 2017-12-29
ES2640563T3 (es) 2017-11-03
BR112012029628B8 (pt) 2022-09-20
ZA201206557B (en) 2013-05-29
MY162921A (en) 2017-07-31
WO2011144745A2 (en) 2011-11-24
CA2796806A1 (en) 2011-11-24
BR112012029628B1 (pt) 2022-08-30
CN103002876A (zh) 2013-03-27
KR101984454B1 (ko) 2019-05-30
KR20180091102A (ko) 2018-08-14
WO2011144745A3 (en) 2012-03-01
RU2641605C2 (ru) 2018-01-18
SG184794A1 (en) 2012-11-29
RU2012155697A (ru) 2014-06-27
US20130259922A1 (en) 2013-10-03
AU2011254553A1 (en) 2012-12-20
US10413511B2 (en) 2019-09-17
EP2394640A1 (en) 2011-12-14
IL222406A0 (en) 2012-12-31
HUE036459T2 (hu) 2018-07-30
JP5966168B2 (ja) 2016-08-10
MX353677B (es) 2018-01-23

Similar Documents

Publication Publication Date Title
BR112012029628A2 (pt) formulações lipossômicas melhoradas de compostos lipofílicos
BR112014029774A2 (pt) uso de n-metil-n-acilglucaminas como agentes espessantes em soluções de tensoativos
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
BR112013005679A2 (pt) imidazopiridazinas substituídas
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
BR112014016633A8 (pt) estruturas fibrosas com múltiplas regiões contendo agente ativo
BR112014029759A2 (pt) uso de n-metil-n-acilglucaminas como solubilizadores
BR112012030653A2 (pt) composição tópica em aerosol, estável ao armazenamento e substancialmente anidra, e, recipiente pressurizado
BR112014023379A8 (pt) Microemulsões com base em ciclodextrina e usos dermatológicos das mesmas
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
WO2011120780A3 (en) Personal wash cleanser with mild surfactant systems comprising defined alkanoyl compounds and defined fatty acyl isethionate surfactant product and optional skin or hair benefit agent
BR112014015333A2 (pt) composições lipossomais de clorito ou clorato
AR092372A1 (es) Formulaciones de liposomas, uso y metodo de tratamiento
BR112014028069A2 (pt) composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
WO2014020167A3 (en) Dye composition comprising at least one sulfonic compound and a thickening polymer, dyeing process and suitable device
WO2013092087A3 (de) Färbemittel mit direktziehenden farbstoffen und phosphat-tensiden
EA201401259A1 (ru) Фторированные мостиковые производные спиро[2,4]гептана в качестве агонистов рецептора alx
BR112015010271A8 (pt) produto de comicronização, processo para o preparo de um produto de comicronização, composição farmacêutica e seus usos
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
WO2012012857A3 (en) Surfactant - free oil- in- water type emulsion, process for preparation and uses thereof
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
WO2013004579A3 (en) Ethers of bis(hydroxymethyl)cyclohexanes
BR112014011824A2 (pt) uso de uma ou várias gomas de silicone em preparados cosméticos ou dermatológicos, e, preparado de aerossol cosmético
WO2011098481A3 (fr) Composition pour cheveux crepus et/ou tres secs

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: SYNCORE BIOTECHNOLOGY CO., LTD (CN)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/05/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2695 DE 30/08/2022 QUANTO AO QUADRO REIVINDICATORIO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.